- Home
- KXIN vs BIAF Comparison
KXIN vs BIAF Comparison
Compare KXIN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- BIAF
- Stock Information
- Founded
- KXIN 2015
- BIAF 2014
- Country
- KXIN China
- BIAF United States
- Employees
- KXIN N/A
- BIAF N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KXIN Consumer Discretionary
- BIAF Health Care
- Exchange
- KXIN Nasdaq
- BIAF Nasdaq
- Market Cap
- KXIN 13.0M
- BIAF 12.2M
- IPO Year
- KXIN N/A
- BIAF 2022
- Fundamental
- Price
- KXIN $0.88
- BIAF $0.31
- Analyst Decision
- KXIN
- BIAF Hold
- Analyst Count
- KXIN 0
- BIAF 1
- Target Price
- KXIN N/A
- BIAF N/A
- AVG Volume (30 Days)
- KXIN 93.5K
- BIAF 11.6M
- Earning Date
- KXIN 01-01-0001
- BIAF 08-13-2025
- Dividend Yield
- KXIN N/A
- BIAF N/A
- EPS Growth
- KXIN N/A
- BIAF N/A
- EPS
- KXIN N/A
- BIAF N/A
- Revenue
- KXIN N/A
- BIAF $8,809,228.00
- Revenue This Year
- KXIN N/A
- BIAF N/A
- Revenue Next Year
- KXIN N/A
- BIAF $20.00
- P/E Ratio
- KXIN N/A
- BIAF N/A
- Revenue Growth
- KXIN N/A
- BIAF 78.40
- 52 Week Low
- KXIN $0.64
- BIAF $0.16
- 52 Week High
- KXIN $29.54
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- KXIN 43.89
- BIAF 51.77
- Support Level
- KXIN $0.89
- BIAF $0.26
- Resistance Level
- KXIN $1.00
- BIAF $0.35
- Average True Range (ATR)
- KXIN 0.07
- BIAF 0.05
- MACD
- KXIN -0.00
- BIAF 0.01
- Stochastic Oscillator
- KXIN 13.88
- BIAF 35.08
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.